Add Row
Add Element
cropper
update
National Cannabis Newswire
update
Add Element
  • Home
  • Categories
    • news
    • trends
    • insights
    • industry
    • legalization
    • health
    • culture
    • advocacy
    • Brands
    • New Mexico Dispensaries
    • Arizona Dispensaries
December 02.2025
3 Minutes Read

Groundbreaking Device Technology and Innovations Honored at 2025 CannaTech Awards

Modern device interface with point of sale software for device technology

Celebrating the Breakthroughs: 2025 CannaTech Award Winners

The cannabis industry is witnessing a defining evolution thanks to daring innovations that aren't just fads but fundamental shifts in technology and processes. The CannaTech Innovation Awards for 2025 showcase a spectrum of cutting-edge advancements that push the boundaries of what we expect from cannabis tech.

Winners Redefining Cannabis Extraction and Device Technology

This year, Curaleaf and its water-based extraction system, Select ACE, stand out by isolating THCA without the harsh chemicals typically involved in extraction. By avoiding ethanol, CO₂, and hydrocarbons, this method results in a purer and clearer oil that consumers rave about for its almost 90 percent THC potency and refined flavor profile. This innovation not only improves consumer satisfaction by reducing throat irritation but also elevates the overall experience of using cannabis products.

Revolutionizing Retail Systems with Smart Software

BLAZE, the second powerhouse on the winners' list, addresses critical pain points in multi-location dispensaries with their smart retail software. Their promotions management tool has dramatically reduced labor hours, allowing retailers to apply promotions across various locations in just a few clicks. This system represents a transformative shift in how cannabis businesses operate, making them more agile and responsive to market demands.

Plant Integrity in the Age of Automation: Ethos Cannabis

Ethos Cannabis is forging a path with its remediation-free cultivation model. Their innovative process eliminates the need for post-harvest remediation through stringent environmental controls and the maintenance of strict hygiene protocols. This model not only preserves the integrity of the terpenes and cannabinoids but also builds consumer trust in a market increasingly focused on product quality and safety.

Flavors Enhanced with Authenticity – The Role of True Terpenes

True Terpenes introduces a unique flavor Modifiers line that enhances original strain identities rather than masking them. This precision-engineered approach allows product developers to introduce targeted sensory effects, a crucial advancement in product development that strengthens both authenticity and consumer appeal.

The Rise of Tech-Savvy Devices: Innovating User Experience

The consumer demand for personalization is reshaping hardware options, as seen in the STIIIZY BAR. Its adjustable features allow users to switch between strains easily. This degree of personalization not only satisfies high-tolerance consumers but also enhances brand loyalty by providing a customizable experience that aligns with user preferences.

Final Thoughts: What This Means for Industry Technologists

The winners of the CannaTech Innovation Awards reflect a significant trend in the cannabis industry—innovation driven by user-centric design and rigorous scientific methodology. As industry technologists, the time to adapt to and embrace these technological advancements is now. Understanding the innovations and mechanisms behind these technologies can position you at the forefront of this burgeoning field.

Stay Ahead of the Curve

In an ever-evolving industry, keeping abrest of the latest trends is crucial. As technology continues to shape the cannabis landscape, consider immersing yourself in these innovations to enhance your understanding and application of cannabis technology. Whether you’re involved in research, product development, or retail, the insights gained from leading innovations can fuel future endeavors.

trends

9 Views

0 Comments

Write A Comment

*
*
Related Posts All Posts

What Medicare’s CBD Coverage Means for Senior Wellness and Industry Tech

Update Shifting Perspectives on CBD for Senior Wellness In recent developments, the prospect of Medicare covering hemp-derived products has ignited discussions about the future of CBD, especially for seniors who rely on these wellness aids. A report from Cannatech Today emphasizes that this move could redefine how older adults access care while revealing the contradictions in current federal regulations. The Historic Move from Medicare The Centers for Medicare & Medicaid Services (CMS) has proposed to cover certain legal CBD products under Medicare Advantage programs, a pivotal shift that recognizes the medicinal potential of non-intoxicating cannabinoids. This initiative could bring relief to the millions of older Americans who have relied on CBD to manage pain, anxiety, and other conditions. Advocates, including organizations like Realm of Caring, hail this change as a much-needed validation that cannabinoids can significantly enhance the quality of life for seniors. Sasha Kalcheff-Korn, the organization’s executive director, mentions that government recognition pushes the body of research for CBD into the forefront of health conversations, making it a legitimate topic within public health discussions. Challenges with Federal Restrictions While the Medicare advancement is promising, a sharp contradiction looms as Congress considers defining hemp more restrictively. The implications of this change are staggering; many current CBD products may become illegal, disrupting access for consumers who rely on them. Price-hikes, product reformulations, and discontinuations await customers if the definition change goes through. This scenario poses immediate risks for seniors who depend on CBD products to manage chronic pain and improve overall wellness. With nearly one-third of Americans aged 50 and over currently utilizing CBD, the potential loss of these products threatens not just individual health but could reverberate through the entire wellness marketplace. Potential Path to Legalization Interestingly, the clash between Medicare's acceptance of CBD and impending federal restrictions may catalyze a push for comprehensive cannabis reform. With a potent political spotlight now on seniors needing accessible CBD products, there might be a greater call for clarity and consistency in legislation. As highlighted in a Forbes article, the conflict introduces an opportunity for advocates to compel lawmakers to recognize the health benefits of cannabinoids beyond the stigma of recreational uses. The duality of these federal messages could ultimately reform how Congress perceives and legislates cannabis. As awareness continues to grow alongside pressure from constituents feeling the consequences firsthand, the industry might finally witness meaningful advancements in legalization efforts. What's Next for the CBD Market? The reality is, without proactive measures, millions of older adults could soon find themselves without access to the products they trust. The current state of uncertainty, however, may also serve as a rallying point for businesses, consumers, and advocates alike. If pushed towards advocacy and engagement, the drive for national cannabis reform could reshape existing conversations around the cannabis industry. Ultimately, as seniors voice their needs, the narrative may shift from prohibition to understanding, potentially leading to a framework that addresses not just CBD, but a wider spectrum of hemp-derived products. Call to Action For those invested in the future of CBD and senior wellness, now is the time to engage. Stay informed about legislative developments, advocate for the rights of seniors to access cannabis products, and consider joining organizations dedicated to education and positive policy changes in this rapidly evolving landscape.

Revolutionizing Epilepsy Treatments: Engineering CBD-like Solutions Without Cannabis

Update Molecular Innovation in Epilepsy Treatment In a groundbreaking study led by researchers at the University of Nevada, Las Vegas (UNLV), the promise of treating pediatric epilepsy is being realized without cannabis-derived products. The research focuses on engineering cannabidiol-like seizure treatments using components derived from the commonplace caraway seed, which may provide a profound advancement in neuropharmacology. The Science Behind the Synthesis By extracting (+)-carvone from caraway's essential oils, the team has successfully synthesized various cannabidiol analogs. This meticulous five-step synthesis process has yielded compounds like (+)-CBD-hex and (+)-CBD-oct, designed to enhance seizure suppression while minimizing psychoactive side effects typically associated with tetrahydrocannabinol (THC). Initial preclinical trials in murine models revealed that these synthetic analogs, particularly (+)-CBD-oct, increased neural stability without causing the sedation seen in existing treatments, such as benzodiazepines. The Impact on Pediatric Patients Dustin Hines, a professor at UNLV, emphasized the critical need for alternatives, stating, "Childhood seizure disorders are often resistant to available drugs. These fully synthetic compounds not only prevent seizures and reduce related deaths but also promote healthier brain cell development." Such progress is vital, as traditional remedies can obstruct cognitive development, severely impacting a child's quality of life. Path to Neurodevelopmental Restoration Beyond their anticonvulsant properties, these caraway-derived compounds are being studied for their potential to normalize neuronal architecture. The results in animal models of epilepsy have been promising, indicating a capacity to rectify abnormal neuronal maturation without the cognitive impairments that benzodiazepines typically cause. "It is encouraging to help build the foundation for future treatment options that could one day offer families safer and more effective choices," noted Adriana Carrillo, a senior at UNLV and co-researcher in the study. Addressing the Treatment Gap in Epilepsy Approximately one-third of epilepsy patients remain treatment-resistant despite various antiseizure medications. The development of synthetic cannabidiol mimics not only fills this gap but also holds the potential to dictate safer therapeutic approaches. As research progresses, understanding the pharmacodynamics and long-term effects of these new compounds will be paramount. Looking Ahead: The Future of Cannabinoid Therapy As the field of neuropharmacology advances, the introduction of synthetic CBD analogs signifies a revolution in epilepsy treatment. With potential implications for broader applications beyond epilepsy, continued research and clinical trials will be necessary to ascertain their efficacy and safety profiles, and to explore the landscape of potential drug interactions. For industry technologists and stakeholders in the medical field, this innovation invites a closer examination of the intersection between traditional botanical extracts and modern pharmaceutical approaches. By supporting further research, we can facilitate the development of treatments that offer hope to families struggling with pediatric epilepsy. Call to Action: Support the Research for Better Treatments Engagement in these advancements is crucial. By advocating for research funding and supporting relevant initiatives within the medical community, stakeholders can play a role in advancing effective therapies for epilepsy and beyond.

Trump's Executive Order: Cannabis Reclassified to Schedule III - What It Means for the Industry

Update Trump's Groundbreaking Move for Cannabis: A Shift in Federal Policy In a transformative executive order signed on December 18, 2025, President Donald Trump directed federal agencies to reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act. This historic shift acknowledges the established medical benefits of cannabis while adjusting its legal perception amid a changing societal landscape. Understanding the Change: What Does Schedule III Mean? Currently, substances classified as Schedule I, such as heroin and LSD, are considered to have no accepted medical use and carry the highest abuse potential. In contrast, Schedule III includes medications like certain steroids and ketamine, both recognized for their medical application with moderate to low risks of abuse. For industry stakeholders and consumers alike, this reclassification signals a significant reduction in the legal stigma surrounding cannabis, allowing for broader acceptance and recognition of its therapeutic potential. Easing Restrictions: A Boom for the Cannabis Industry The immediate impact of this policy includes the potential elimination of IRS Section 280E, a longstanding hurdle barring cannabis companies from deducting ordinary business expenses. Tax rates could drop from exorbitant levels of 70-90 percent to around 20 percent, akin to other industries. This financial relief could empower cannabis businesses, promoting hiring, innovation, and capital influx, echoing sentiments from leaders like Brian Vicente of Vicente LLP, who highlights the monumental positive effect this will have on state-legal cannabis enterprises. The Broader Implications of Cannabis Reclassification While this reclassification does not legalize recreational use federally, it opens the door for enhanced medical research by streamlining the approval process for studies related to cannabis's medical applications. The White House emphasizes an increased focus on research to inform patients and healthcare providers, bridging gaps in medical guidelines that currently exist due to restrictive regulations. Industry Reactions: Acknowledgment and Anticipation Industry leaders view this executive order as a vital step forward. Ben Kovler, CEO of Green Thumb Industries, expressed that the move validates the therapeutic uses of cannabis known by millions. Cristy Aranguiz, a CEO in the sector, shared that this change significantly benefits patients relying on cannabis for pain relief and improved quality of life, emphasizing the intersection of advocacy and real-world impact. Challenges Ahead: Understanding the Limits of Rescheduling Despite the progress heralded by this decision, federal possession of cannabis without a prescription remains illegal, highlighting that rescheduling alone does not fully eliminate the discrepancies between state and federal policies. As cautionary notes echo across the industry, there remains a call for Congress to take further steps towards comprehensive legalization. Conclusion: The Future of Cannabis Industry Dynamics This landmark decision could catalyze significant changes within the cannabis industry, a sector poised for rapid growth and evolving regulatory landscapes. With a heightened focus on delving into the scientific understanding of cannabis, continued advocacy, and legislative efforts tailored towards full legalization appear more promising than ever. Now is the time for industry professionals to navigate this shifting terrain carefully, balancing innovation with compliance in a world where cannabis is increasingly recognized for its valuable contributions to health and wellness.

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*